Metafort G2 CP Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. This dual-action formulation offers complementary mechanisms to effectively lower blood glucose levels in patients inadequately controlled by diet and exercise alone. Metafort G2 CP Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. The extended-release formulation ensures a sustained therapeutic effect, minimizing fluctuations in blood sugar levels and enhancing patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which usually subside with continued use. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. Metafort G2 CP Tablet PR should be used under medical supervision to optimize glycemic control and reduce the risk of diabetes-related complications.